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in type 2 diabetic patients
Galyna Mykhalchyshyn, Nazarii Kobyliak* and Petro BodnarAbstract
Background: Ghrelin is a hormone produced mainly by the cells lining the fundus of the stomach, which is
involved in regulation of lipid and glucose metabolism. Two major forms of ghrelin can be found in circulation: an
acylated form, and non-acylated form. Serum acyl-ghrelin (AG) concentration is significantly increased in patients
with visceral obesity and insulin resistance. This study was conducted to evaluate changes in serum AG levels, its
diagnostic accuracy and association with NAFLD in patients with type two diabetes (T2D).
Methods: In this cross-sectional study, 91 T2D patients, age of 40–80 years, were included. All patients were divided into
3 groups. The control group included 28 T2D patients without NAFLD. The main group included 63 T2D patients with
NAFLD, which was divided in 2 subgroups depending on transaminase levels: normal (n = 37) and elevated (n = 26)
transaminases group. To assess the diagnostic accuracy of AG for NAFLD we used ROC-analysis.
Results: We observed 1.5 (p = 0.016) and 2.5 (p < 0.001) fold increasing of serum AG levels in patients with NAFLD and
normal or elevated transaminases compared to control groups. In multivariate logistic regression analysis high AG level
was an independent, from transaminases activity, triglycerides (OR 1.791; 95 % CI 1.162–2.759; p = 0.008) and degree of IR
(OR 1.599; 95 % CI 1.019–2.508; p = 0.044) predictor that associated with NAFLD. When serum AG used as non-invasive
marker for NAFLD detection AUROC was 0.835 (95 % CI 0.752–0.918, p < 0.001). The cut-off value was >0.52 ng/ml, with
sensitivity, specificity, PPV and NPV – 60.3 %, 92.8 %, 95.0 %, 50.9 % respectively. For distinguishing patients with NAFLD
and elevated transaminases from patients with NAFLD and normal values AG was less effective.
Conclusions: Our study has demonstrated that elevated AG level were associated with NAFLD. Patients with elevated
transaminases had significantly higher AG levels. An increase of AG over 0.52 ng/ml can be used as a diagnostic marker
for NAFLD detection in patients with T2D.
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Non-alcoholic fatty liver disease (NAFLD), the hepatic
counterpart of the metabolic syndrome (MS) [1], encom-
passes a disease spectrum spanning simple steatosis
through nonalcoholic steatohepatitis (NASH) with/without
cirrhosis, and hepatocellular carcinoma [2]. The obesity
and type 2 diabetes (T2D) pandemic and the improved
management of chronic viral hepatitis, have resulted in
NAFLD becoming a leading cause of chronic liver disease* Correspondence: nazariikobyliak@gmail.com
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article, unless otherwise stated.[3, 4] and a major health concern owing to hepatic and ex-
trahepatic morbidity/mortality [5].
NAFLD pathogenesis as a two-hit model was initially
proposed by Day and James [6]. First, IR causes lipid accu-
mulation in hepatocytes and lead to development of fatty
liver; second, cellular insults such as oxidative stress, lipid
oxidation, and chronic inflammation result in NASH. In
patients with NAFLD, the intrahepatic TG content seems
to depend mainly on the systemic availability of free fatty
acids (FFA). This was suggested by isotope labeling studies
in which serum FFA were shown to account for 59 % of
hepatic TG [7]. Therefore fatty liver develops when de
novo synthesis exceed the oxidation and re-secretion ofCentral. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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increased FFA supply due to increased lipolysis from both
visceral/subcutaneous adipose tissue as a result of IR [8];
(2) increased intake of dietary fat sources of FFAs; (3) in-
creased de novo lipogenesis [9]; (4) alteration in the syn-
thesis or secretion of lipoproteins [10]; (5) reduction in
mitochondrial FA β-oxidation [11]. There is evidence that
rate of de novo lipid synthesis is elevated in livers of pa-
tients with NAFLD, compared with healthy subjects [12].
A shift from FA oxidation to de novo lipid synthesis is me-
diated by an increased activity of the transcription factors
PPAR-γ [13], ChREBP and SREBP-1c [14], all of which are
positive modulators of hepatic TG contents by targeting
genes coding for key reactions in lipid synthesis.
Ghrelin is a 28 amino-acid peptide with an n-octanoyl
group at the serine three residue, produced mainly by the
stomach, which was identified as the endogenous ligand of
the growth hormone secretagogue receptor (GHS-R) [15].
Administration of exogenous ghrelin reportedly enhances
appetite and increases food intake through the activation of
hypothalamic neuropeptide Y/agouti-related peptide neu-
rones expressing GHS-R type 1a [16]. In addition to potent
GH-releasing activity, ghrelin is involved in the peripheral
levels influencing lipid metabolism [17] and glucose
homeostasis by regulating insulin secretion and sensitivity
in pancreatic b-cells [18] and by stimulating glucose output
by primary hepatocytes [19].
The preproghrelin gene-derived peptides include acyl
ghrelin (AG), DAG, and obestatin [1]. Earlier studies on
ghrelin and energy balance and metabolism were performed
by total ghrelin assays. It was decreased in obesity, insulin
resistance (IR) and T2D [16, 19]. DAG is the major circulat-
ing form and constitutes 80–90 % of circulating ghrelin.
Although it was originally thought that DAG lacked endo-
crine and biological actions, more recent findings suggest
that both AG and DAG may mediate peripheral biological
actions; indeed, there is a suggestion that both may act an-
tagonistically [20, 21]. Therefore, the aim of this study was
to explore the potential role of AG in NAFLD and to assess
it diagnostic accuracy as non-invasive marker.
Materials and methods
Study subjects
In this cross-sectional study, 112 T2D patients with age of
40–80 years from the Kyiv City Clinical Endocrinology
Center were selected. Inclusion criteria were: age over
18 years, presence of T2D in association with or without
NAFLD. NAFLD diagnosis was concluded according to the
recommendations of the American Gastroenterology Asso-
ciation (AGA) and American Association for the Study of
Liver Disease (AASLD) on the basis of next: clinical exam-
ination, laboratory values of lipid and carbohydrate metab-
olism, liver enzyme activities (ALT, AST), ALT/AST ratio,
and ultrasonography (US) examination [22]. Exclusioncriteria included alcohol abuse (>210 grams of alcohol per
week in men and >140 g of alcohol per week in women
over a two-year period), chronic viral hepatitis (associated
with HBV, HCV, HDV infection), drug-induced liver dis-
ease, Wilson’s disease, hereditary deficiency of antitrypsin-1
and idiopathic hemochromatosis. We met criteria of eligi-
bility in 91 T2D patients which were included in this study.
In 21 patients we found comorbid etiology with signs of
others chronic liver disease: 15 of them were seropositive
for chronic viral hepatitis, 6 patients have alcohol abuse an-
amnesis. These patients were excluded from our study. The
ethics committee of Kyiv City Clinical Endocrinology Cen-
ter approved the study.Data collection and measurements
After informed consent, fasting serum samples were ob-
tained and immediately frozen at−80 °C. For each patient,
relevant clinical and demographic data were collected.
Anthropometric data including weight and height were
measured to the nearest 100 g and 0.5 cm, respectively.
Body mass index (BMI) was calculated as body weight in
kilograms divided by the square of the participant’s height
in meters.
Plasma total cholesterol (TC), HDL-cholesterol (HDL-C)
and triglyceride (TG) concentrations were measured using
enzymatic kits, standardized reagents and standards (Bio-
Vendor, Czech Republic). LDL-cholesterol concentration
was calculated using the Friedewald equation [23]. Blood
glucose was determined using the Trinder’s glucose oxidase
method while serum insulin was measured with the double
radioimmunoassay (RIA) method (AIA-Pack IRI; Tosoh,
Tokyo). Insulin resistance was assessed by the validated
homeostasis model assessment (HOMA) index [24] using
the following formula: HOMA-IR = (FPG * FPI)/22.5,
where FPG and FPI are fasting plasma glucose (mmol) and
fasting plasma insulin (μU/ml), respectively.
The diagnosis of fatty liver was based on the results of
abdominal ultrasonography, which was done by trained
technicians with Ultima PA (Radmir Co., Kharkiv, Ukraine).
Of 4 known criteria (hepatorenal echo contrast, liver
brightness, deep attenuation, and vascular blurring) [25],
the participants were required to have hepatorenal contrast
and liver brightness to be given a diagnosis of NAFLD.
Also for confirmation of NAFLD diagnosis especially
in case of US negative or contradictory data we used
computer-assisted quantitative US techniques assess-
ment. In these cases we used software programs to
analyze US echo attenuation or calculate hepato-renal
index which defined as the ratio of the echo intensities
of the liver and renal cortex. These parameters have
demonstrated higher sensitivities (>90 %) and specificity
((>90 %)) for mild steatosis detection (≥5 %) as com-
pared to routine B-mode US [26, 27].
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plasma samples stored at −20 °C using a commercial “pep-
tide enzyme immunoassay” kit (Peninsula Laboratories, Inc.,
California, USA) with intra-assay and inter-assay variations
of coefficients (CV) of less than 5 % and 14 %, respectively,
sensitivity limit of 0.08-1.0 ng/ml, and measuring range of
0–25 ng/ml. No cross-reactivity was found with human des-
acyl ghrelin, motilin, secretin, human vasoactive intestinal
peptide, human prolactin-releasing peptide-31, human gala-
nin, human growth hormone releasing hormone, neuropep-
tide Y, orexin A, orexin B.
Statistical analysis
The SPSS statistical package, version 20.0 (SPSS, Inc.,
Chicago, Illinois) was used for all statistical analyses and a P
value less than 0.05 was considered statistically significant.
All continuous values are expressed as mean ± SD and cat-
egorical variables are presented as %. Data distribution was
analyzed using the Kolmogorov-Smirnov normality test.
Continuous variables with parametric distribution were
then analyzed using Analysis of Variance (ANOVA) and if
the results were significant, a Bonferroni Post Hoc test was
performed. Data with non-parametric distribution was ana-
lyzed using Kruskall-Wallis test. For comparisons of cat-
egorical variables we conducted χ2 test.
Univariate and multivariate logistic regression analyses
were used to identify the risk factors of NAFLD. The
odds ratios are given with the 95 % confidence intervals.
Variables which are statistically significant in univariate
analysis were included in the multivariate logistic regres-
sion analysis. Backward stepwise selection was used at aTable 1 Anthropometric, clinical and laboratory parameters in exam
Parameters Control p1 p2 NAFLD with norma
(n = 28) (n = 37)
Age, years 53.57 ± 7.16 - - 53.27 ± 8.39
Duration of T2D, years 5.0 ± 2.81 - - 5.97 ± 3.88
BMI, kg 31.15 ± 3.0 0.028 <0.001 34.46 ± 5.64
ALT, U 25.03 ± 7.26 NS <0.001 28.93 ± 6.15
AST, U/L 23.91 ± 6.11 NS <0.001 26.6 ± 5.71
FPI, μIU/ml 11.21 ± 3.58 0.001 <0.001 18.27 ± 8.14
FPG, mmol/l 7.80 ± 1.41 - - 8.67 ± 3.25
HOMA-IR 3.86 ± 1.41 <0.001 <0.001 6,86 ± 3.21
TC, mmol/l 5.68 ± 0.68 0.004 <0.001 6.24 ± 0.72
TG, mmol/l 1.83 ± 0,45 0,018 <0,001 2,65 ± 1,2
VLDL-C, mmol/l 0.82 ± 0.2 0.005 <0.001 1.25 ± 0.59
HDL-C, mmol/l 1.66 ± 0.25 0.001 <0.001 1.43 ± 0.24
LDL-C, mmol/l 3.18 ± 0.6 0.047 <0.001 3.61 ± 0.69
p - the difference between all study groups calculated using one-way ANOVA
p 1-3 - for pairwise comparisons used Bonferroni Posthoc test
p1 - the difference between the control and normal transaminases groups
p2 - the difference between the control and elevated transaminases groups
p3 - the difference between normal and elevated transaminases groupsstringency level of p < 0.10 to detect the independent
risk factors on NAFLD. A p < 0.05 probability level was
considered as statistically significant.
To assess the diagnostic accuracy of AG for NAFLD de-
tection and differentiation patients with normal and ele-
vated transaminases values we used receiver operating
characteristic (ROC) curves. The ROC curve is a plot of
sensitivity (Se) vs 1-specificity (Sp) for all possible cut-off
values. The most commonly used index of accuracy is area
under the ROC curve (AUROC). AUROC-values close to
1.0 indicated high diagnostic accuracy. Optimal cut-off
values were chosen to maximize the sum of sensitivity and
specificity, and positive (PPV) and negative predictive
values (NPV) were computed for these cut-off values.
Results
All patients were divided on the next groups. The control
group included 28 (30.76 %) T2days patients without
NAFLD (mean age was 53.57 ± 7.16, T2D duration 3.5 ±
1.57). The main group included 63 (69.24 %) T2D patients
with NAFLD, which was divided in 2 subgroups depend-
ing on transaminase levels: normal transaminases group
included 37 (58.73 %) patients (mean age was 53.27 ± 8.39,
T2D duration 5.97 ± 3.88 years) and respectively elevated
transaminases group included 26 (41.27 %) patients with
mean age 51.5 ± 10.92 and T2D duration 8.54 ± 5.57 years.
Results of anthropometric, clinical and laboratory pa-
rameters are represented in the Table 1. There was no
statistically significant difference in the T2D duration
between all study groups (p = 0.068). The longest dur-
ation of T2D was observed in patients with NAFLD andined patients (M ± SD)
l transaminases NAFLD with elevated transaminases p3 p
(n = 26)
51.5 ± 10.92 - NS
8.54 ± 5.57 - NS
40.35 ± 5.63 <0.001 <0.001
64.96 ± 14.99 <0.001 <0.001
55.8 ± 11.91 <0.001 <0.001
20.61 ± 8.56 NS <0.001
9.48 ± 3.14 - NS
8.23 ± 2.85 NS <0.001
6.56 ± 0.62 NS <0.001
3,36 ± 1,55 NS <0,001
1.39 ± 0.63 NS <0.001
1.2 ± 0.26 0.002 <0.001
4.07 ± 0.78 0.034 <0.001
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We found significant increasing of BMI parallel to
NAFLD presence and it severity. The prevalence of
obesity (defined as BMI>30.0) in control group was
64.3 %, while in NAFLD patients the rate were higher:
75.7 % for normal transaminases and 100 % for elevated
transaminases group (p = 0.004) respectively. Morbid
obesity (BMI>40.0) was diagnosed only in patients with
NAFLD (16.2 % vs 46.2 %, p < 0.001).
In all patients we found violation of the carbohydrate
metabolism. Mean values of HOMA-IR and insulinemia
were higher in NAFLD patients with maximum on
elevated transaminases groups (p < 0.001). The value of
HOMA-IR exceeding 3 (indication of IR) were found in
78.6 % of patients from control group, in NAFLD groups,
depending of transaminase activity, we determine IR in
94.6 % and 96.2 % patients respectively (p = 0.048).
Dyslipidemia was present in all study patients. We
observed growth of TC (p < 0.001), TG (p < 0.001), VLDL-C
(p < 0.001) and LDL-C (p < 0.001) parallel with the develop-
ment of NAFLD and activity of transaminase. While HDL-
C levels decreased. Highest mean lipid levels were observed
in patients with NAFLD and elevated transaminases.
Level of serum AG was significantly higher in patients
with NAFLD compared to the control group (Fig. 1).
We also mentioned significant difference between mean
AG values in NAFLD patients depending on transamin-
ase activity (0.53 ± 0.19 vs 0.83 ± 0.41, p = 0.001).
In univariate logistic regression analysis independent pre-
dictors, associated with the development NAFLD in pa-
tients with T2D were HOMA-IR (OR 2.026; 95 % CI
1.409–2.914; p < 0.001), insulin (OR 1,307; 95 % CI 1.140–
1.500; p < 0.001), BMI (OR 1.296; 95 % CI 1.130–1.436; p <
0.001), ALT (OR 1.121; 95 % CI 1.051–1.196; p–0.001) and
AST (OR 1.128; 95 % CI 1.052–1.196, p–0.001). The level
of AG was also independently associated with NAFLD de-
velopment (OR 2.104; 95 % CI 1.465–3.021; p < 0.001).Fig. 1 Serum AG levels in study patientsAll variables which were statistically significant in
univariate analysis were included in the stepwise multi-
variate logistic regression analysis. As seen in Table 2
we constructed several regression models. From which
AG was an independently from transaminases activity,
level of TG (Nagelkerke R2 = 0,624) and degree of IR
(Nagelkerke R2 = 0,529) associated with the NAFLD
development.
Establishing a statistically significant difference between
mean AG levels in patients with and without NAFLD we
created a background for assessment of diagnostic efficacy
of this hormone in diagnosing NAFLD. In these purposes,
we have used ROC-analysis. We have plotted 2 ROC-
curves (Fig. 2).
The first ROC-curve was used to analyze AG as a pre-
dictor for NAFLD diagnosis. In this model we included
overall data from patients with NAFLD independent of
transaminase activity and compared it to subjects with
T2D without NAFLD. We determined the quality of this
diagnostic model as very good since AUROC for AG
was 0.835 (95 % CI 0.752–0.918, p < 0.001) (Fig. 2,
Table 3). The cut-off value of AG for NAFLD diagnosing
in patients with T2D was >0.52 ng/ml. Sensitivity, speci-
ficity, PPV and NPV were 60.3 %, 92.8 %, 95.0 %, 50.9 %
respectively.
The 2nd ROC-curve was constructed to analyze AG effi-
cacy in differentiating patients with NAFLD and normal
or elevated transaminases. The quality of this diagnostic
model was describes as poor, since AUROC for ghrelin
was 0.753 (95 CI 0.625–0.880, p = 0.001). The cut-off
value for ghrelin for diagnosing elevated transaminases in
patients with NAFLD and T2D was >0.84 ng/ml. Sensitiv-
ity, specificity, PPV and NPV were 50.0 %, 91.8 %, 81.2 %,
72.3 % respectively (Table 3).
Discussion
NAFLD is characterized by accumulation of TG in the
hepatocytes as well as other inflammatory and fibrotic
changes in the hepatic parenchyma. Our study assesses
the potential connections between NAFLD and serum
AG concentrations in T2D patients. The first available
data mentioned a negative association between total
ghrelin and NAFLD. Marchesini et al. when compared
to 40 matched healthy subjects, suggested that patients
with NAFLD (n = 86) had reduced level of total ghrelin.
After adjustment for age and sex, significantly associated
with low ghrelin (below 235pmol/l) in the whole group
was only HOMA-IR (OR 5.79; 95 % CI 2.62–12.81; p <
0.0001) [28]. Tacke et al. reported that total ghrelin
levels are elevated in elevated in Child C cirrhosis pa-
tients independent of the etiology of chronic liver dis-
eases. Ghrelin did not correlate with liver function, but
associated with clinical (gastrointestinal bleeding, ascites,
encephalopathy) and biochemical (anemia, inflammatory
Table 2 Multiple stepwise logistic regression analysis using NAFLD as dependent variable and as independent predictors all factors
that were significant associated in univariate analysis
Models Regression coefficient ± SE OR (95 % CІ) p
Model 1 (Nagelkerke R2 = 0,624)
Constant -8.971 ± 2.32
Acyl-ghrelin 0.583 ± 0.221 1.791 (1.162–2.759) 0,008
ALT 0,116 ± 0.046 1.123 (1.026–1.230) 0,012
TG 1.811 ± 0.701 6.119 (1.548–24.183) 0.010
Model 2 (Nagelkerke R2 = 0,569)
Constant -5.984 ± 1.675
Acyl-ghrelin 0.469 ± 0.230 1.599 (1.019–2.508) 0.041
HOMA-IR 0.386 ± 0.191 1.471 (1.010–2.140) 0.044
AST 0.099 ± 0.046 1.104 (1.008–1.208) 0.033
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[29].
Therefore role of different ghrelin forms are still
contradictory. We reported 1.5 (p = 0.016) and 2.5 (p <
0.001) fold increasing of serum AG levels in patients
with NAFLD and normal or elevated transaminases
compared to control groups. Our data in concordance
with the study of Estep et al [30]. They reported, in 75
morbidly obese patients with biopsy-proven NAFLD (41
with histologic NASH), that circulating AG concentra-
tions in NASH with fibrosis score ≥2 were almost
double the concentration of NASH patients with a fibro-
sis stage <2 (8.73 vs. 4.22 pg/ml, p < 0.04). However no
significant differences in AG levels between NASH and
patients with non-NASH (6.42 ± 15.0 vs 2.85 ± 6.0,
p>0.05) authors did not found. From the other hand
Gutierrez-Grobe et al. [31], in cross-sectional study in-
cluded 98 subjects (51 NAFLD patients and 47 controls),
found that compared to control NAFLD patients had
significantly lower level of serum ghrelin. In multivariate
logistic regression analyses high ghrelin (OR = 0.128, 95
CI 0.048–0.343, p < 0.001) level had a protective effectFig. 2 ROC-curves using as a predictor AG for NAFLD diagnosis (a) and disagainst hepatic steatosis after controlling for potential
confounders. The limitations of this study were lack of
liver biopsy and image-based NAFLD diagnosis. Also the
authors used an assay without using protease inhibitors
that are essential to protect AG from being de-acylated,
which questions what peptides are really involved in
their observed associations [32]. Due to our data high
AG level was an independent, from transaminases activ-
ity, TG (OR 1.791; 95 % CI 1.162–2.759; p = 0.008) and
degree of IR (OR 1.599; 95 % CI 1.019–2.508; p = 0.044)
predictor that associated with NAFLD development in
patients with T2D.
Recent study showed that incubation with both AG
and DAG, in differentiating omental adipocytes, signifi-
cantly increased PPAR-γ and SREBP1 mRNA levels, as
well as several fat storage–related proteins, including
acetyl-CoA carboxylase (ACC), fatty acid synthase (FAS),
lipoprotein lipase (LPL) and perilipin [33]. Consequently,
both the ghrelin forms may play a role in excessive fat
accumulation in obesity and thereby NAFLD.
Also in state of NAFLD elevated concentrations and
systemic availability FFA may promote increased ghrelintinguish patients with different degree of transaminase activity (b)
Table 3 Diagnostic accuraccy of AG for NAFLD diagnosis and differentiation between patients with elevated and normal values
Parameter NAFLD vs Control NAFLD (normal vs elevated transaminases)
Cut-off value <0.52 <0,84
Sensitivity, % 60.3 50.0
Specificity, % 92.8 91.8
NPV, % 50.9 72.3
PPV, % 95.0 81.2
AUROC 0.835 0.753
95 % CІ 0.752–0.918 0.625–0.880
p (AUROC) <0,001 0.001
NPV negative predictive value, РPV positive predictive value, AUROC area under ROC-curve, 95%CІ 95 % confidence interval for AUROC
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for the elevated circulating AG [34]. Nishi et al. report that
ingestion of either medium-chain fatty acids (MCFAs) or
medium-chain triacylglycerols (MCTs) increased the stom-
ach concentrations of AG without changing the total (acyl-
and des-acyl) ghrelin amounts in mice [35]. Interestingly,
Yang et al. [36] have recently identified a novel enzyme im-
plicated in the n-octanoylation of ghrelin, namely GOAT
(Ghelin O-Acyltransferase), that is expressed in the major
ghrelin-secreting tissues. It seems plausible that obesity in-
fluences the expression and/or activity of this acyltransfer-
ase, leading to elevated plasma concentrations of AG.
Conclusion
In conclusion, our data indicate that relative AG excess is
associated with NAFLD in T2D patients independently of
IR, transaminases activity and TG levels. We first provided
the assessment of diagnostic accuracy of AG for NAFLD
diagnosis and distinguishing patients with different degree
of transaminase activity and concluded high specificity
(>90 %) with lower value of sensitivity (50–60 %). Further-
more investigations will be needed to elucidate whether
dysregulation of ghrelin secretion profiles in NAFLD pa-
tients may influence the long-term metabolic outcomes.
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